Systemic immune activation and microbial translocation in dual HIV/tuberculosis-infected subjects

Journal of Infectious Diseases

Volumn 207, Issue 12, 2013, Pages 1841-1849

  Toossi, Zahra ^a,b   Funderburg, Nicholas T ^a   Sirdeshmuk, Sohani ^a   Whalen, Christopher C ^c   Nanteza, Maria W ^d   Johnson, Denise F ^a   Mayanja Kizza, Harriet ^a,d,e   Hirsch, Christina S ^a  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b LOUIS STOKES CLEVELAND VA MEDICAL CENTER   (United States)

^c UNIVERSITY OF GEORGIA   (United States)

^d MAKERERE UNIVERSITY   (Uganda)

^e JOINT CLINICAL RESEARCH CENTRE   (Uganda)

Author keywords

HIV 1; LPS; soluble CD14; tuberculosis

Indexed keywords

ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; CD14 ANTIGEN; CD163 ANTIGEN; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; TUBERCULOSTATIC AGENT;

ADULT; ARTICLE; BLOOD LEVEL; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE ACTIVATION; IMMUNE RESPONSE; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MICROBIAL TRANSLOCATION; MICROBIOLOGICAL PHENOMENA AND FUNCTIONS; MIXED INFECTION; MYCOBACTERIUM TUBERCULOSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SPUTUM CULTURE; TREATMENT DURATION; TUBERCULOSIS; VIRUS LOAD;

HIV-1; LPS; SOLUBLE CD14; TUBERCULOSIS;

ADULT; ANTIGENS, CD14; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ANTITUBERCULAR AGENTS; BACTERIAL TRANSLOCATION; CASE-CONTROL STUDIES; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; GASTROINTESTINAL TRACT; HIV INFECTIONS; HIV-1; HUMANS; LIPOPOLYSACCHARIDES; MALE; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS, PULMONARY; UGANDA; VIRAL LOAD;

EID: 84878001437     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jit092     Document Type: Article

References (32)

1. Lawn SD, Wood R, Wilkinson RJ. Changing concepts of "latent tuberculosis infection" in patients living with HIV infection. Clin Dev Immunol 2011. doi: 10.1155/2011/980594.
2. Daley CL, Small PM, Schecter GF, et al. An outbreak of tuberculosis with accelerated progression among persons infected with the human immunodeficiency virus: an analysis using restriction-fragment-length polymorphisms. N Engl J Med 1992; 326:231-5.
3. Lopez-Gatell H, Cole SR, Margolick JB, et al. Effect of tuberculosis on the survival of HIV-infected men in a country with low tuberculosis incidence. AIDS 2008; 22:1869-73.
4. Whalen C, Horsburgh CR, Hom D, Lahart C, Simberkoff M, Ellner J. Accelerated course of human immunodeficiency virus infection after tuberculosis. Am J Respir Crit Care Med 1995; 151:129-35.
5. Toossi Z. Virological and immunological impact of tuberculosis on human immunodeficiency virus type 1 disease. J Infect Dis 2003; 188:1146-55.
6. Kizza HM, Rodriguez B, Quinones-Mateu M, et al. Persistent replication of human immunodeficiency virus type 1 despite treatment of pulmonary tuberculosis in dually infected subjects. Clin Diagn Lab Immunol 2005; 12:1298-304.
7. Nanteza MW, Mayanja-Kizza H, Charlebois E, et al. A randomized trial of punctuated antiretroviral therapy in Ugandan HIV-seropositive adults with pulmonary tuberculosis and CD4 T-cell counts of ≥350 cells/μL. J Infect Dis 2011; 204:884-92.
8. Hertoghe T, Wajja A, Ntambi L, et al. T cell activation, apoptosis and cytokine dysregulation in the (co)pathogenesis of HIV and pulmonary tuberculosis (TB). Clin Exp Immunol 2000; 122:350-7.
9. Goletti D, Weissman D, Jackson RW, et al. Effect of Mycobacterium tuberculosis on HIV replication; role of immune activation. J Immunol 1996; 157:1271-8.
10. Hazenberg MD, Otto SA, van Benthem BH, et al. Persistent immune activation in HIV-1 infection is associated with progression to AIDS. AIDS 2003; 17:1881-8.
11. Butler SL, Valdez H, Westby M, et al. Disease-modifying therapeutic concepts for HIV in the era of highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2011; 58:297-303.
12. Wright SD. CD14 and innate recognition of bacteria. J Immunol 1995; 155:6-8.
13. Sandler NG, Wand H, Roque A, et al. Plasma levels of soluble CD14 independently predict mortality in HIV infection. J Infect Dis 2011; 203:780-90.
14. Anas A, van der Poll T, de Vos AF. Role of CD14 in lung inflammation and infection. Crit Care 2010; 14:209.
15. Weaver LK, Hintz-Goldstein KA, Pioli PA, et al. Pivotal advance: activation of cell surface Toll-like receptors causes shedding of the hemoglobin scavenger receptor CD163. J Leukocyte Biol 2006; 80: 26-35.
16. Burdo TH, Lentz MR, Autissier P, et al. Soluble CD163 made by mono-cyte/macrophages is a novel marker of HIV activity in early and chronic infection prior to and after antiretroviral therapy. J Infect Dis 2011; 204:154-63.
17. Brenchley JM, Price DA, Schacker TW, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nature Med 2006; 12:1365-71.
18. Jiang W, Lederman MM, Hunt P, et al. Plasma levels of bacterial DNA correlate with immune activation and the magnitude of immune restoration in persons with antiretroviral-treated HIV infection. J Infect Dis 2009; 199:1177-85.
19. Marchetti G, Bellistri GM, Borghi E, et al. Microbial translocation is associated with sustained failure in CD4+ T-cell reconstitution in HIV-infected patients on long-term highly active antiretroviral therapy. AIDS 2008; 22:2035-8.
20. Redd AD, Dabitao D, Bream JH, et al. Microbial translocation, the innate cytokine response, and HIV-1 disease progression in Africa. Proc Natl Acad Sci USA 2009; 106:6718-23.
21. Redd AD, Gray RH, Quinn TC. Is microbial translocation a cause or consequence of HIV disease progression? J Infect Dis 2011; 203:744-5; author reply 746.
22. Cassol E, Malfeld S, Mahasha P, et al. Persistent microbial translocation and immune activation in HIV-1-infected South Africans receiving combination antiretroviral therapy. J Infect Dis 2010; 202:723-33.
23. Hirsch CS, Toossi Z, Johnson JL, et al. Augmentation of apoptosis and interferon-gamma production at sites of active Mycobacterium tuberculosis infection in human tuberculosis. J Infect Dis 2001; 183:779-88.
24. Alwis KU, Milton DK. Recombinant factor C assay for measuring en-dotoxin in house dust: comparison with LAL, and (1→3)-beta-D-glucans. Am J Ind Med 2006; 49:296-300.
25. Juffermans NP, Verbon A, van Deventer SJ, et al. Serum concentrations of lipopolysaccharide activity-modulating proteins during tuberculosis. J Infect Dis 1998; 178:1839-42.
26. Gutsmann T, Muller M, Carroll SF, MacKenzie RC, Wiese A, Seydel U. Dual role of lipopolysaccharide (LPS)-binding protein in neutralization of LPS and enhancement of LPS-induced activation of mononuclear cells. Infect Immun 2001; 69:6942-50.
27. Mahan CS, Walusimbi M, Johnson DF, et al. Tuberculosis treatment in HIV infected Ugandans with CD4 counts >350 cells/mm reduces immune activation with no effect on HIV load or CD4 count. PloS ONE 2010; 5:e9138.
28. Marchetti G, Nasta P, Bai F, et al. Circulating sCD14 is associated with virological response to pegylated-interferon-α/ribavirin treatment in HIV/HCV coinfected patients. PLoS ONE 2012; 7: e32028.
29. El-Sadr WM, Lundgren JD, Neaton JD, et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 2006; 355:2283-96.
30. Abdool Karim SS, Naidoo K, Grobler A, et al. Integration of antiretrovi-ral therapy with tuberculosis treatment. N Engl J Med 2011; 365: 1492-501.
31. Tincati C, Biasin M, Bandera A, et al. Early initiation of highly active antiretroviral therapy fails to reverse immunovirological abnormalities in gut-associated lymphoid tissue induced by acute HIV infection. Antivir Ther 2009; 14:321-30.
32. Berg RK, Melchjorsen J, Rintahaka J, et al. Genomic HIV RNA induces innate immune responses through RIG-I-dependent sensing of secondary-structured RNA. PloS ONE 2012; 7:e29291.